PDCD1 and neoplasm: In vivo, mice treated with paclitaxel, T4 cells and repeated doses of anti-PD-1 antibody had a significant reduction in their tumor burden compared to mice receiving paclitaxel alone, anti-PD-1 antibody alone, or T4 cells alone (Fig. 6b, c).